References

• Aquila Bioscience has developed a ground-breaking new barrier spray making re-usable masks up to 99% effective at blocking airborne pathogens and particles. Marketing & Communications Office; Mar 11, 2021
• Irish Company Develop Technology Proven to Remove 99.99% of Coronavirus from Human Skin. Marketing & Communications Office; October 28, 2020.
• Aquila Bioscience is selected for EIC Accelerator Funding. European Commission; June 8, 2020.

• Local medtech company develops mask spray which blocks 99 per cent of pathogens. Galway Advertiser; Mar 11, 2021.
• Green Innovator: Aquila lancia la prima salvietta anti-coronavirus 100% naturale. Enterprise Ireland, The Irish Advantage Italian Version
• Galway medtech develops mask spray to block 99% of pathogens by Lisa Ardill. Siliconrepublic; Mar 8, 2021.
• NUIG spin-out develops mask spray that blocks 99% of pathogens. Galway Bay FM; Mar 8, 2021.
• Medtech mask spray blocks 99% of pathogens
• Irish Innovation in Wipes and Masks Could Help Battle Emerging Coronavirus Crisis. NUI Galway Marketing & Communications Office; Jan 27, 2021.
• ‘Living Velcro’ used to trap viruses by Elaine O’Regan. Business Post; Feb 11, 2022.
• Innovation is key in battle against Covid-19 by Sylvia Thompson. Irish Times; May 12, 2020.
• An emerging Irish technology may be key to containing the Wuhan coronavirus. GRIPT; Feb 27, 2020.
• First consignment of Galway-manufactured wipe that can help fight SARS-CoV-2 delivered to Defence Forces. Galway Bay FM; April 14, 2020.
• Higher Education Research Activity in response to SARS-CoV-2: Higher Education Research Activity in response to SARS-CoV-2 by Maura O’Shea. HEA Newsletter; May 27, 2020.
• NOVEL DECONTAMINATION WIPE TO PREVENT SPREAD OF SARS-CoV-2. Irish Defence Forces Newsletter; April 2020.

Aquila Bioscience Ireland EDF June 2022

FDA Registration: Aquila Bioscience have been successfully registered as a foreign manufacturing facility for the ABD Device with the FDA under Owner/ Operator Number 10074735

NeoVirTech: French Laboratory of expertise has proven the efficiency of the ABD Device in its ability to capture and remove up to 99.99% of SARS CoV-2 from the human skin.

International Patent Application WIPO 2020/240027 A1. Device and method for decontamination / disinfection.

• 07-2020-07/2022 (Ongoing), EIC Accelerator (H2020-EIC-SMEInst-2018-2020-3), COVID-19 pandemic: An innovative, safe and effective bio-decontamination technology for non-toxic removal of biological agents, including coronavirus (Grant agreement ID: 959436), EU contribution: €1,941k (Overall budget: €2,773k)
• 04/2017-04/2021 (Delivered), ITN PathSense (Pathogen Sensing), ABL cost: none/student secondments (total cost €3,385k)
• 01/2018 – 06/2018 (Delivered), Glyco-DeCon Feasibility Study (SMEInst-13-2016-2017 Phase I) to verify financial feasibility and review the Intellectual property landscape, EU H2020 SMEInst ABL cost: €71k (total cost €71k)
• 04/2015 – 04/2017 (Delivered), DCLAW: Decontamination by Carbohydrate Lectin Affinity Wipes European Defence Agency, ABL cost: €132k (total cost €248k)
• 05/2014 – 04/2017 (Delivered), NAPES: Next Generation Analytical Platforms for Environmental Sensing, EU FP7-NMP, ABL cost: €480k (total cost €4,539k)